NCT03741179View on ClinicalTrials.gov

Detection of False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of Pregnancy

PHASE3CompletedINTERVENTIONAL
Enrollment

974

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

January 30, 2022

Study Completion Date

January 30, 2022

Conditions
Pre-Eclampsia
Interventions
DRUG

ASA-withdrawn group

Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.

Trial Locations (1)

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT03741179 - Detection of False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of Pregnancy | Biotech Hunter | Biotech Hunter